|Day Low/High||148.07 / 153.50|
|52 Wk Low/High||42.97 / 176.50|
After recent weakness in the biotech sector, here are some names to start watching.
Building on PPMD's 10-Year-Old Duchenne Registry, the largest Patient Reported Outcomes Registry for the Disease, and Sarepta Therapeutics' Leadership with the First U.S.-Approved Therapy, New Interchange is Scheduled for 2019 Launch
This is a healthy pullback in a market that was a little overheated.
Despite $5.1 billion deal for Costa, I'm not slurping any KO up.
You don't have to be Sigmund Freud to understand the psychology here.
If estimates continue to come up there will be institutional interest in the stock.
There are several key points to keep in mind as you digest this news.
If the market wanted an excuse to sell off it had it.
Jim Cramer weighs in on Sony, United Rentals, Marathon Petroleum, Royal Dutch Shell, Lam Research, NuStar Energy, Ebix and more.
Walmart -- with great growth -- sparks optimism, but Jim Cramer says it's not the only stock to fuel the day's rally.
After rallying to more than $100 a share, the stock could pull back to around $95 before consolidating gains.
The market has wanted to sell-off for a while and finally it is doing it.
While markets are higher Tuesday, there is little to suggest recent choppy action won't continue.
The bounce this morning is producing a sigh of relief, but this is going to remain a difficult trading market.
For a long time now one of the most consistent patterns in the market has been buying dips created by negative headlines.
Apple in particular is helping the bullish cause.
Small and mid-cap biotech firms are driving innovation in the sector. Experts explain why investors should take notice.
Sarepta Therapeutics, Inc. (Nasdaq: SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases, and non-profit CureDuchenne announced today they have...
There are issues in the study that are keeping some buyers cautious and causing selling into the early strength.
Everyone is a buyer of pullbacks when the market is going up but not so much when it's going down.
There are likely to be some good opportunities developing as this profit taking accelerates.
Sarepta adds another 7% on top of nearly 40% gains on Tuesday following good results for a new gene therapy.
Sentiment is very positive, regardless of what the indices may say.
The S&P 500 has shown the same pattern for three consecutive days.
But rival firm PTC Therapeutics tumbles nearly 31% on the news.
It is important for the bulls that the indices close near the highs of the day.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.